Chemistry:Belvarafenib

From HandWiki
Short description: Investigational cancer drug
Belvarafenib
Belvarafenib.svg
Clinical data
Other namesHM95573

GDC5573

RG6185
Routes of
administration
By mouth
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC23H16ClFN6OS
Molar mass478.93 g·mol−1
3D model (JSmol)

Belvarafenib (developed by Hanmi Pharmaceuticals and Genentech) is a small molecule RAF dimer (type II) inhibitor[1] which shows anti-tumor clinical activity in cancer patients with BRAFV600E- and NRAS- mutations.[2]

References

  1. "Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights". Current Opinion in Oncology 34 (2): 115–122. March 2022. doi:10.1097/CCO.0000000000000817. PMID 35050937. 
  2. "Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.". Journal of Clinical Oncology 37 (15 suppl): 3000. 31 May 2019. doi:10.1200/JCO.2019.37.15_suppl.3000.